IMMUTEP Aktie

>IMMUTEP Aktienkurs

0.16 EUR (Tradegate)

Ask: 0.16 EUR / 10000 Stück

Bid: 0.15 EUR / 10000 Stück

Tagesumsatz: 0 Stück

Realtime Kurs von 8 bis 22 Uhr!

Intraday

1 Jahr

>IMMUTEP Performance

1 Woche: +2,5%

1 Monat: +8,0%

3 Monate: +31,7%

6 Monate: +63,6%

1 Jahr: +839,1%

laufendes Jahr: -1,2%

>IMMUTEP Aktie

Name:

IMMUTEP LTD

Land:

Australien

Sektor:

Gesundheit

ISIN/ Wkn:

AU000000IMM6 / A2H81H

Symbol/ Ticker:

YP1B (Frankfurt)

Kürzel:

FRA:YP1B, YP1B.F, YP1B:GR

Index:

Webseite:

https://www.immutep.com/

Marktkapitalisierung:

73.87 Mio. EUR

Umsatz:

EBITDA:

Gewinn je Aktie:

-0.003 EUR

Schulden:

Liquide Mittel:

Umsatz-/ Gewinnwachstum:

23.40% / -

KGV/ KGV lG:

- / -

KUV/ KBV/ PEG:

12.96 / 3.58 / -

Gewinnm./ Eigenkapitalr.:

-98.03% / -46.69%

Dividende je Aktie:

Dividendenrendite/ -schätzung:

- / -

Suchwörter:

IMMUTEP

Letzte Datenerhebung:

28.10.20

>IMMUTEP Eigentümer

Aktien: 492.87 Mio. St.

f.h. Aktien: 453.04 Mio. St.

Insider Eigner: 6.41%

Instit. Eigner: 6.85%

Leerverk. Aktien: -

>IMMUTEP Peer Group

AVITA THERAPEUTICS CDIS

CLINUVEL

GENETIC TECHNOLOGIES

MMJ GROUP

NANOSONICS

OPTHEA

POLYNOVO

PRO MEDICUS

STARPHARMA

THC GLOBAL

>IMMUTEP Chart & Kurs - Stuttgart
- Boerse Frankfurt
- Boerse Stuttgart

>IMMUTEP News

29.10.20 - 13:48	Immutep to Collaborate with LabCorp to Develop Oncology Services and Products (GlobeNewswire EN)
	SYDNEY, Australia, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, is pleased to announce that it has entered into a Li...

23.10.20 - 14:12	Immutep Announces the Start of an Investigator-Initiated Phase II Study in COVID-19 Patients (GlobeNewswire EN)
	SYDNEY, Australia, Oct. 23, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), is pleased to announce it has signed a Material Transfer Agreement (“Agreement”) with the University Hospital Pils...

22.10.20 - 06:42	Why is the Immutep (ASX:IMM) share price falling lower today? (Fool)
	The Immutep share price is falling today after the company announced its quarterly results for the September quarter. We take a closer look. The post Why is the Immutep (ASX:IMM) share price falling lower today? appeared first on Motley Fool Australi...

22.10.20 - 00:48	Immutep Activities Report for the First Quarter of Fiscal Year 2021 (GlobeNewswire EN)
	SYDNEY, Australia, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, today provided a business update for the quarter end...

21.10.20 - 19:55	Immutep nabs European patent covering IMP761 (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

21.10.20 - 16:49	Why Immutep′s Stock Is Trading Higher Today (Benzinga)
	Immutep (NASDAQ: IMMP) shares are trading higher on Wednesday after the company was granted a European patent for its IMP761. read more...

21.10.20 - 14:06	Immutep Granted European Patent for IMP761 (GlobeNewswire EN)
	SYDNEY, Australia, Oct. 21, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, is pleased to ann...

19.10.20 - 14:06	Immutep to Present AIPAC Overall Survival Data at the San Antonio Breast Cancer Symposium 2020 (GlobeNewswire EN)
	SYDNEY, Australia, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, is pleased to ann...

25.09.20 - 14:02	IMMUTEP Ltd: 20-F Report (SEC Filing)
	20-F...

18.09.20 - 08:16	Immutep presents improving results from INSIGHT-004 trial (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

18.09.20 - 08:01	Immutep reports encouraging results from mid-stage TACTI-002 study (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

18.09.20 - 03:37	Immutep (ASX:IMM) share price flying 20% on improving trials (Fool)
	The Immutep share price is flying today as the company reported improvements in trials relating to its leading drug IMP321. The post Immutep (ASX:IMM) share price flying 20% on improving trials appeared first on Motley Fool Australia....

18.09.20 - 02:24	Immutep Announces Improving Results from Stage I of Phase II TACTI-002 Study (GlobeNewswire EN)
	SYDNEY, Australia, Sept. 18, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) announces new interim data from its ongoing Phase II TACTI-002 study. The data was presented in two poster presentations at the ESMO Virtual Congress 202...

18.09.20 - 01:54	Immutep Reports Improving Results from INSIGHT-004 Trial (GlobeNewswire EN)
	SYDNEY, Australia, Sept. 18, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) is pleased to report further interim data from its ongoing INSIGHT-004 Phase I clinical trial. The data were presented at the ESMO Virtual Congress 2020 ...

31.08.20 - 14:03	Immutep and Monash University Receive Grant Funding for LAG-3 Project (GlobeNewswire EN)
	SYDNEY, Australia, Aug. 31, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) is pleased to announce that the Australian Research Council (ARC) has awarded Immutep and research partner Monash University a A$671,427 grant under the A...

26.08.20 - 14:03	New Data From Immutep′s efti to be Presented at ESMO (GlobeNewswire EN)
	SYDNEY, Australia, Aug. 26, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is pleased to an...

18.08.20 - 14:03	Immutep Completes Recruitment for Stage 1 of Part B in TACTI-002 Study (GlobeNewswire EN)
	SYDNEY, Australia, Aug. 18, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is pleased to re...

23.07.20 - 15:36	Thinking about buying stock in Entera Bio, Immutep, Electrameccanica Vehicles, Delta Air Lines, or Carnival Corp? (PR Newswire)
	NEW YORK , July 23, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ENTX, IMMP, SOLO, DAL, and CCL....

15.07.20 - 18:19	Mid-Day Market Update: Nasdaq Turns Negative; Immutep Shares Spike Higher (Benzinga)
	Midway through trading Wednesday, the Dow traded up 0.45% to 26763.36 while the NASDAQ fell 0.25% to 10,462.34. The S&P also rose, gaining 0.39% to 3,210.08. read more...

15.07.20 - 17:13	Immutep up 52% on U.S. patent covering LAG-3 technology (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Zitat des Tages: Wie respektabel die Leut′ sind, das soll man nie auf′n ersten Blick beurteil′n, weil man sich beim zweiten nur zu oft vom Gegenteil überzeugt. - Johann Nepomuk Nestroy

Partner: >Tradegate Börse | >TraderFox Handelssignale | >Heibel-Ticker Börsenbrief | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf Twitter